Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-318; Location: LEVEL 3, HALL B3; P3 | "Immediate ruxolitinib-to-momelotinib transition is not associated with severe or acute symptom relapses. Events were generally infrequent, low-grade, and transient. These findings inform symptom management expectations during ruxolitinib-to-momelotinib switch in patients with myelofibrosis."
Clinical • P3 data • Retrospective data • Myelofibrosis • Oncology
|
|
Pankit Vachhani MD 1; Alessandro Lucchesi MD 2; Andrew Charles Perkins MD 3; Jasmine Sahni PharmD 4; Mahshid Azimi PharmD 4; Jessica Lim MA 4; Shiyuan Zhang MSc 4; Dwaipayan Patnaik MD 5; Jeanne M Palmer MD 6; Prithviraj Bose MD 7
|